Idorsia Ltd (0RQE.IL)
- Globe Newswire
Idorsia announces changes to Idorsia Executive Committee and Board of Directors
Ad hoc announcement pursuant to Art. 53 LR Jean-Paul Clozel to retire as CEO and stand for election as Chairman of the Board of DirectorsMathieu Simon to stand for re-election to the Board – taking on the role of Vice-Chairman and Lead Independent DirectorAndré C. Muller, current CFO of Idorsia, to take over the role of CEO as of June 13, 2024 Allschwil, Switzerland – May 21, 2024Idorsia Ltd (SIX: IDIA) today announced changes to the Idorsia Executive Committee (IEC) and will propose changes in
- Globe Newswire
Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2024. Business highlights Viatris collaboration: Global research and development collaboration, focused on the development and commercialization of two innovative compounds, selatogrel and cenerimod. Commercial highlights QUVIVIQ™ (daridorexant): Total net sales of CHF 10 million in Q1 2024.QUVIVIQ in the US: Citizens petition to
- Globe Newswire
Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year of 2023. Business highlights Sale of Idorsia Asia-Pacific operations (excluding China): Sold to Nxera Pharma (previously known as Sosei Heptares) for a total consideration of CHF 400 million in July 2023.Cost reduction initiative: Delivering a 50% reduction in fixed cost at Swiss headquarters fully effective in early 2024.Aprocitentan: Wo
